Erkang Pharmaceutical (300267.SZ) issued an advance loss. The net loss is expected to be 148 million yuan to 198 million yuan in 2023, changing from profit to loss

According to the Zhitong Finance App, Erkang Pharmaceutical (300267.SZ) disclosed the 2023 annual results forecast. The company expects a net loss of 148 million yuan to 198 million yuan attributable to shareholders of listed companies, from profit to loss; net loss of 185 million yuan to 235 million yuan after deducting non-recurring profit and loss.

During the reporting period, the prices and sales volume of the company's intermediates and some auxiliary products all declined significantly. At the same time, the company's development of new businesses led to an increase in expenses, which had a certain impact on profits.